Paragon Biosciences company gets $250M • Lurie's $25M health center
Crain's Health Pulse is your source for actionable, exclusive and inside news on the health care industry.
Source: chicagobusiness.com
📰 Chicago Based Emalex News
Chicago Based Emalex News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Chicago Based Emalex. Real-time updates on events, politics, business and more.
Bain Capital-Backed Emalex Bio Lands $250M for Pivotal Test of Tourette Drug
Emalex Biosciences will use the cash from its Series D financing to conduct a Phase 3 clinical trial for ecopipam, an experimental treatment for Tourette syndrome. Though there drugs are already available for Tourette, Emalex’s drug addresses a different central nervous system target that the biotech believes could offer an edge.
United States Emalex Bioscience Bain Capital Life Sciences American Academy Of Neurology Fidelity Management Research Company Psyadon Pharmaceuticals
Source: medcitynews.com
Emalex raises $250 million for Tourette's drug development | Crain's Chicago Business
Emalex plans to use the money to launch the largest North American clinical trial for a Tourette Syndrome drug and to potentially bring the drug to market.
Eric Messner Emalex Biosciences Us Food Drug Administration Chicago Based Emalex Drug Administration Emalex Chief Business Officer Eric
Source: chicagobusiness.com